1. Home
  2. RDHL

as 06-06-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Founded: 2009 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 3.8M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 214.4K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -6.71 EPS Growth: N/A
52 Week Low/High: $1.71 - $20.27 Next Earning Date: 04-10-2025
Revenue: $8,042,999 Revenue Growth: 23.17%
Revenue Growth (this year): 381.91% Revenue Growth (next year): N/A

RDHL Daily Stock ML Predictions

Share on Social Networks: